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The participation of B and T cells in an immune response requires their separate activation by
different forms of the target antigen. In this issue of Immunity, Pape et al. (2007) describe antigen
entry into the B cell areas in the lymph node without degradation or cellular assistance.It is axiomatic to immunology that
challenge by antigen elicits a response
specific for the antigen. The produc-
tion of antigen-specific antibodies re-
quires, in certain circumstances, the
collaboration of B and T helper lym-
phocytes that recognize physically
linked antigenic determinants. Estab-
lishing this collaboration, however, is
fraught with difficulty; the frequency
of antigen-specific lymphocytes may
be extremely low, and those that exist
may be in the anatomical equivalents
of the opposite ends of the earth. Ad-
ditionally, B and T cells ‘‘see’’ antigen
in fundamentally different ways. Hur-
dling these barriers to a productive
response is achieved in large part
by focusing the components of the
response in the anatomical structures
that constitute the secondary lym-
phoid organs; lymph nodes, spleen,
tonsil, and Peyer’s patches. The report
by Pape et al. (2007) in this issue of
Immunity provides a startling insight
into the means by which the coordina-
tion necessary to initiate an immune
response is achieved by addressing
the deceptively simple question of
how a B cell in a lymph node encoun-
ters a soluble antigen that has entered
the host at a distant site.
The work of Pape et al. (2007) exam-
ines how antigen enters a lymph node;
is it cell-associated or free? Once in-
side the lymph node, are B cells able
to recognize antigen without the assis-
tance of, for example, dendritic cells?
Once having recognized the antigen,
are B cells activated and able to pres-
ent the antigen in a form recognizable
by T cells? These may seem some-
what esoteric details, but the manner
and context in which B cells ‘‘see’’
antigen has important implications for
resolving infections, vaccine develop-388 Immunity 26, April 2007 ª2007 Elsevment, and autoimmunity. Before con-
sidering the experiments of Pape
et al. (2007) and the insights they pro-
vide, it is important to understand the
context in which the work was done,
which in turn requires an understand-
ing of lymph node architecture.
Lymph nodes are encapsulated by
a dense layer of connective tissue
with bundles of collagen fibers called
trabeculae extending from the capsule
into the parenchyma of the node (Fig-
ure 1). They are connected to the
blood supply through an artery and
vein and to the lymphatic system
through vessels called the afferent
and efferent lymphatics. The afferent
lymphatics bring fluid from the tissues
into the node and drain into the sub-
capsular sinus that separates the cap-
sule from the cortex. Within lymph no-
des B and T, lymphocytes segregate
into specific areas with B cells residing
predominantly in the cortex, adjacent
to the subcapsular sinus, in regions
called follicles. Germinal centers,
when they develop, do so in follicles.
T cell areas flank the follicles and ex-
tend toward the center of the node,
called the paracortex. The paracortex
is the area where blood-borne lym-
phocytes enter the node via high
endothelial venules (HEV). Lympho-
cyte extravasation across the HEV
into the node is mediated by specific
adhesion molecules such as CD62L
and can be blocked by antibodies,
thus effectively isolating the node
from blood-borne lymphocytes. The
core of the node is called the medulla,
which following immunization contains
plasma cells organized along medul-
lary cords. The medulla also contains
sinuses that coalesce to form the ef-
ferent lymphatic vessel, draining the
node. Another level of organizationier Inc.was recently defined when fine con-
duits were described that were formed
by collagen fibers wrapped in fibro-
blastic reticular cells (Gretz et al.,
2000). These conduits are considered
a primary route for movement of mate-
rial, including soluble antigen and
immune modulators, from the subcap-
sular sinus through the paracortex to
the space surrounding the HEV (Gretz
et al., 2000). There are studies report-
ing the acquisition of antigen by den-
dritic cells (DC) that are associated
with these conduits in the paracortex
(Sixt et al., 2005), suggesting this as
a means of antigen entry into nodes.
However, these conduits are frequent
in the paracortex but sparse in the
follicles (Gretz et al., 1996), indicating
they may be less important for antigen
entry into the follicles.
So, in this organized and partitioned
structure, how can antigen be deliv-
ered to those cells that have to see it,
B cells in the follicles and T cells in
the paracortex? T cells see antigen af-
ter processing and presentation by
professional antigen-presenting cells.
DC in the nodes can acquire antigen
in one of three ways. First, as outlined
above, is acquisition from antigen
moving through the conduits (Sixt
et al., 2005). Second is migration of
antigen-laden DC from tissue into the
node following exposure to antigen.
Third, antigen-exposed interstitial DC
may hand off antigen to lymph-node-
resident DC before entering the para-
cortex (Allan et al., 2003). Thesemech-
anisms all bring antigen into the node
in a cell-associated form and by routes
that are concentrated in T-cell-rich
areas. As such, they are ideal for ex-
posing both resident and migrating
T cells to antigen but less so for acti-
vating B cells, which would have to
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PreviewsFigure 1. Representation of a Lymph Node Showing Pathways of Antigen Entry
B cell (F, follicles) and T cell areas (PC, paracortex) are marked as are medullary sinus, high endo-
thelial venules, afferent and efferent lymphatics, and the subcapsular sinus. Antigen enters the
node either cell associated (pathway A) or free (pathway B). Pathway A results in the antigen mov-
ing within conduits (C) from the subcapsular sinus to the paracortex where it can be picked up by
DC. Pathway B, described by Pape et al. (2007), concentrates free antigen in the follicles where it
can activate B cells.enter into the paracortex to encounter
antigen—ignoring for the moment the
relatively infrequent movement of DC
from the paracortex into the follicles.
This would limit antigen exposure to
those B cells that entered the node via
the blood, leaving B cells in the follicles
ignorant of an immunological challenge
for which they may be specific. It also
implies that B cells must be able to
both ‘‘see’’ the antigen bound to the
DC surface and acquire sufficient
amounts for processing and presenta-
tion to T cells. This, indeed, seems to
occur. Studies from Qi et al. (2006)
show clearly that when antigen is
bound to DC, it is transported into the
node and there can stimulate anti-
gen-specific B cells. Previous work
shows that high-affinity B cells (fortu-
itously using the same model antigen
as Qi and Pape) are able to extract an-
tigen from membranes for subsequent
processing and presentation (Batista
and Neuberger, 2000). Similarly, stud-
ies of the activation of B cells in
response to blood-borne antigens
show DC capturing antigen and trans-
porting it to the splenic marginal zone
for B cell activation (Balazs et al.,
2002). Collectively, these studies sup-port the notion that antigen enters into
nodes in a cell-assisted manner, prob-
ably by DC, where it is then acquired
by B cells (Figure 1, pathway A). Pre-
sumably this activity would be limited
to those B cells that entered the lymph
node via the HEV, crossing the para-
cortex on their way to the follicles
and therefore having the opportunity
to encounter such antigen-laden DC.
There are, however, data that do not
fit this model, such as experiments
showing subcutaneously injected anti-
gen appearing rapidly in the lymph
node in a cell-free state (Beh and
Lascelles, 1985). Moreover, there are
teleological objections that antibody
usually needs to recognize a native
structure (for example, the protective
antibodies against influenza), so it
would seem important for B cells to
see native antigen, unconstrained or
masked by DC binding. Pape et al.
(2007) have addressed some of these
concerns with an elegant system. The
authors used green fluorescent protein
(GFP) coupled to hen egg lysozyme
(HEL) as their antigen. The GFP was
modified by appending a peptide se-
quence, which when presented in the
context of MHC II I-Ab, is recognizedImmuniin by a particular monoclonal antibody.
Thus, by using anti-HEL immuno-
globulin transgenic B cells, Pape
et al. (2007) controlled the frequency
and distribution of antigen-specific
B cells while the tripartite antigen
allowed them to monitor antigen loca-
tion and the degree of processing
and presentation by both B cells and
DC. Two additional aspects of the ex-
perimental system are worth noting.
These were to use in some experi-
ments DC expressing the diptheria
toxin receptor (DTR) as a transgene
under the CD11c promoter, meaning
DC frequency could be dramatically
reduced independently of B cell fre-
quency. Second was to use a mono-
clonal antibody specific for CD62L to
block entry of B cells into the LN via
the HEV,meaning that only the cells al-
ready in the lymph node were available
for responding to antigen.
The results can be summarized as
follows: minutes after subcutaneous
injection of antigen, antigen-specific
B cells in the node acquired, pro-
cessed, and presented antigen and
did so with greater efficiency and ra-
pidity than DC. Antigen appeared in
the subcapsular and connected si-
nuses and the follicles within minutes
of subcutaneous injection, well before
it appeared in the T cell area (Figure 1,
pathway B).
Activation of B cells in the follicle
was related to their proximity to the si-
nus, not to the conduit network. Fol-
lowing exposure to antigen, resident
follicular B cells migrated to the T-B
border and were able to produce anti-
body-secreting cells at a normal fre-
quency without a significant contribu-
tion from blood-borne B cells, whose
entry into the node was blocked by
anti-CD62L. The findings were not de-
pendent on the high affinity interaction
of the transgenic B cell receptor for the
model antigen, as endogenous B cells
behaved in the same way to GFP as
the transgenic B cells did to HEL.
There are of course caveats and
cautions associated with the work
that need to be borne in mind in inter-
preting the data. Antigen was injected
with small amounts of lipopolysaccha-
ride (LPS) added as an adjuvant, and
one does not know precisely the effect
this may have had on B cell behavior inty 26, April 2007 ª2007 Elsevier Inc. 389
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Previewsaddition to that induced by antigen.
Second, the antigen was created by
chemical conjugation of HEL with
GFP, which created a range of mul-
timeric forms. It is not clear whether
aspects of B cell activation or anti-
gen distribution were dependent on
or related to a particular degree
of multimerization and additionally
whether some of the injected antigen
was in a particulate rather than soluble
form.
Do the data of Pape et al. [2007] re-
fute the previous findings? Absolutely
not, but they reveal—again—the ex-
traordinary diversity of the immune
system such that it is able to dealHold On, the Mon
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The role that monocyte-derived d
show that these cells develop ‘‘on
T helper 1 immune response.
For many immunologists, the term
‘‘dendritic cell’’ (DC) evokes one type
of immunosurveilling leukocyte, dis-
tributed throughout the body, ready to
respond to pathogens that breach the
physical barriers that protect us from
infection. To carry out this function,
DCs possess highly effective mecha-
nisms to detect and capture patho-
gens at the site of infection. Such an
encounter triggers migration of DCs to
the T cell areas of the spleen and lymph
nodes, where DCs present pathogen
antigens to T cells to initiate immunity
(Wilson and Villadangos, 2005). In con-
trast to this ‘‘one-size-fits-all’’ descrip-
tion of the DC life cycle, we now know
that DCs are heterogeneous and com-
prise distinct subtypes that vary in he-
matopoietic origin, life cycle, and func-
tional capabilities (Shortman and Naik,
2007; Villadangos and Heath, 2005).
How the different components of this
390 Immunity 26, April 2007 ª2007 Elseviwith challenges that arrive via multiple
routes and in multiple forms. Antigen
may arrive for presentation both free
and as DC bound. It is possible, how-
ever, that B cells are preferentially
stimulated by the former route and T
cells by the latter. Optimizing the mix
of antigen types could maximize the
immune responses induced.
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